世界肺癌會議英文學習教案

1、會計學1世界世界(shji)肺癌會議英文肺癌會議英文第一頁，共33頁。第1頁/共33頁第二頁，共33頁。Chemotherapy used in IALT Adjuvant chemotherapy regimen % of the ptsCisplatin 300-400mg/m2 over 3-4 cycles withetoposidevinovelbinevinblastinvindesine5627116第2頁/共33頁第三頁，共33頁。第3頁/共33頁第四頁，共33頁。第4頁/共33頁第五頁，共33頁。Chemotherapy armControlP valueMedian sur

2、vival50.8 months44.4 months0.035-year survival rate44.5%40.4%Median disease-free survival40.2 months 30.5 months0.0035-year disease-free survival rate39.4%34.3%Lethal toxicity rate0.8%0The overall survival hazard ratio for chemotherapy was 0.86 95% CI=0.76-0.98Absolute 5-year survival benefit of 4.1

3、%Absolute 5-year disease-free survival benefit of 5.1%, and hazard ratio was o.83%第5頁/共33頁第六頁，共33頁。MMC/VLB/DDP NVB/DDP, or no chemotherapy第6頁/共33頁第七頁，共33頁。第7頁/共33頁第八頁，共33頁。stage or stage第8頁/共33頁第九頁，共33頁。第9頁/共33頁第十頁，共33頁。第10頁/共33頁第十一頁，共33頁。第11頁/共33頁第十二頁，共33頁。第12頁/共33頁第十三頁，共33頁。第13頁/共33頁第十四頁，共33頁。Size

4、 and hazard ratio of overall survival in recent large adjuvant studiesHazard ratio for chemotherapy95% CInNSCLCCG1,394o.870.74-1.02ALPI1,2090.960.81-1.13IALT1,8690.860.76-0.98BLT3811.020.77-1.35第14頁/共33頁第十五頁，共33頁。第15頁/共33頁第十六頁，共33頁。第16頁/共33頁第十七頁，共33頁。第17頁/共33頁第十八頁，共33頁。第18頁/共33頁第十九頁，共33頁。第19頁/共33頁第二

5、十頁，共33頁。Comparison of every-3-weeks versus weekly docetaxelDocetaxel 75mg/m2every 3 weeksDocetaxel 36mg/m2weeklyP valueResponse rate8%5%NSTTP2.7 months2.9 monthsNS1-year survival rate29.2%21.8%NSMedian survival7.1 months5.4 monthso.o4第20頁/共33頁第二十一頁，共33頁。Comparison of every-3-weeks versus weekly doce

6、taxel第21頁/共33頁第二十二頁，共33頁。Pemetrexed versus Docetaxel第22頁/共33頁第二十三頁，共33頁。Efficacy of pemetrexed versus docetaxelMedian survivalHazard ratio (95% CI)Pemetrexed (n=283)Docetaxel (n=288)1-year survival rateTime to progressionHazard ratio (95% CI)Response rate8.3 months7.9 monthso.99(0.8-1.2)29.7%29.7%2.

7、9 months2.9 months0.97(0.8-1.2)9.1%8.8%第23頁/共33頁第二十四頁，共33頁。Grade toxicity of pts of pemetrexed versus docexelPemetrxedn=285DocetaxelN=276P valueNeutropeniaNeutropenia feverThrombcytopeniaNeuropathy (grade 2-4)Hospitalization due to Fever and neutropenia5%2%2%3%2%40%13%1%8%16%0.00010.0001o.1160.0140.

8、0001第24頁/共33頁第二十五頁，共33頁。第25頁/共33頁第二十六頁，共33頁。第26頁/共33頁第二十七頁，共33頁。Gefitinib (Irresa)Safety and Tolerability第27頁/共33頁第二十八頁，共33頁。Gefitinib (Irresa)Pts with BAC and never smokePts with either non-smoker or BAC histology Pts who were smoker with non-BAC histologyRRMST55%14 months26%9 months6%4 months Pts with nonadenocacinoma0Memorial Sloan-Kettering Ca